Skip to main content
Jonathan Peled, MD, Oncology, New York, NY

JonathanUPeledMDPhD

Oncology • New York, NY

Hematologic Oncology

Physician

Request Appointment

Overview of Dr. Peled

Dr. Jonathan Peled is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 7 years. He is one of 495 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 90 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2017
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 2010 - 2013
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 2010

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2013 - 2026
  • NJ State Medical License
    NJ State Medical License 2019 - 2025
  • MA State Medical License
    MA State Medical License Active through 2013
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation  
    Jonathan Peled, MD, The New England Journal of Medicine

Abstracts/Posters

  • Antibiotic Exposures and Dietary Intakes Are Associated with Changes in Microbiota Compositions in Allogeneic Hematopoietic Stem Cell Transplant Patients
    Jonathan U. Peled, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • The Blood Microbiome Predicts Acute Graft-Versus-Host Disease after Stem Cell Transplantation
    Jonathan U. Peled, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Pre-Transplant Fecal Microbial Diversity Independently Predicts Critical Illness after Hematopoietic Cell Transplantation
    Jonathan U. Peled, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Inferior survival after microbiota injury: A multicenter allo-HCT study. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Dysgeusia Is Associated with Higher Melphalan Pharmacokinetic Levels and Results in Poorer Caloric Intake and Worse Symptom Burden after Autologous Stem Cell Transplan... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • The Gut Microbiome and Cancer: MSK Researchers Present New Findings
    The Gut Microbiome and Cancer: MSK Researchers Present New FindingsApril 19th, 2023
  • Your Gut Microbes Can Help Fight Cancer, New Research Reveals
    Your Gut Microbes Can Help Fight Cancer, New Research RevealsSeptember 27th, 2022
  • ASCO 2021 Research Roundup: Focus on Immunotherapy
    ASCO 2021 Research Roundup: Focus on ImmunotherapyJune 7th, 2021
  • Join now to see all

Dr. Jonathan Peled, Dr. Jonathan Peled, MD, Dr. J Peled, Dr. Jonathan U Peled